The Supportive Effect of Acarbose to Orlistat in Weight Management—A Randomized, Double‐Blind, Multiarm Phase 2 Trial
Authors' conclusion
Acarbose enhances the weight loss efficacy of EMP16, supporting its potential as a safe and effective treatment for long-term obesity management.
Study context
- Population
- Individuals with obesity or overweight and comorbiditiesrandomized equally
- Participants
- 240 individuals
- Comparison
- EMP16 vs MR-O vs Conv-O
- Primary endpoint
- Relative and categorical weight loss
- Follow-up
- 6 months
Methodological detailsdouble-blind, multiarm, phase 2
- Double-blind
- Multiarm
- Phase 2
Primary result
As reported in the abstract
Mean relative weight loss
Mean relative weight loss · 6 months EMP16 mean −7.73 % · MR-O mean −5.78 % · Conv-O mean −5.13 %
≥ 5% weight reduction
≥ 10% weight reduction
P > 0.05 for ≥ 10%
- EMP16 vs MR-O: P < 0.01 — relative weight loss, across EMP16, MR-O and Conv-O
Further findings
| Outcome | P value |
|---|---|
| Fatty liver index and quality of lifeEMP16 vs Conv-O · greater improvement with EMP16 | P < 0.01 |
Glucose and lipid markers
- All groups showed small improvements in glucose and lipid markers
Safety
- Serious adverse events
- 0
- Most AEs were mild and transient
Original publication
The Supportive Effect of Acarbose to Orlistat in Weight Management—A Randomized, Double‐Blind, Multiarm Phase 2 Trial. Obesity (Silver Spring). Published 6 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →